TILRAY BRANDS INC

Tilray Brands Inc. stock rose 2.2% on Aug 5 after a Strong‑Buy upgrade by TD Securities, with insider buys, record 2026 growth, and analysts targeting $11.00.

Tilray Brands posts Q4 loss but FY2026 revenue hits $915M; 2027 guidance aims for $68‑$75M EBITDA and margin growth.

Tilray Brands pivots from beer to Texas spirits and launches discreet THC pouches, aiming to diversify amid cannabis market volatility and regulatory uncertainty.

Tilray Brands Inc. gears up for July 28 earnings, weighing cannabis volatility, a BrewDog pub event, and a downgraded analyst outlook.

Tilray Brands joins Frankfurt Stock Exchange, boosting European liquidity and investor reach for the cannabis & hemp leader.

Tilray Brands expands medical cannabis for UK veterans, launching a dedicated Lyphe clinic program amid DEA scrutiny—evidence‑based relief for veterans.

Tilray Brands Q3 tops expectations with record revenue, a narrowed loss, and a positive EPS, yet market sentiment remains cautious amid high valuation and ongoing net‑loss pressure.

Tilray Brands faces a pivotal pivot: Wall Street shifts from “Sell” to “Hold” as the company expands into Australia and partners with Cheba Hut, yet its earnings lag, valuation strains, and volatile stock keep investors wary. Explore whether this me…

Tilray Brands expands its medical cannabis portfolio in Australia, partners with Breckenridge Distillery for U.S. growth, yet faces stock volatility amid market uncertainty.

Tilray Brands surges as cannabis moves to Schedule III, launching Tilray Medical USA to tap a growing U.S. medical market—investors eye a new growth wave.